Sofosbuvir
Active Pharmaceutical Ingredients 2025-03-03
English synonyms Psi-7977 (S)-2-{(S)-[(2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy](phenoxy)phosphorylamino}propionic acid isopropyl ester
Catalog ID92111
CAS NO.1190307-88-0
Purity 97%
MDL NumberMFCD18782704
Molecular Formula C22H29FN3O9P
Molecular Weight 529.453”
| Category | Content |
|---|---|
| Generic Name | Sofosbuvir |
| Brand Name | Sovaldi, Harvoni (in combination with ledipasvir) |
| Chemical Formula | C22H29FN3O9P |
| CAS Number | 777862-06-0 |
| Mechanism of Action | Sofosbuvir is a nucleotide analog inhibitor that specifically targets the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It is metabolized intracellularly to form an active uridine analog triphosphate (GS-461203), which incorporates into the viral RNA and acts as a chain terminator, preventing viral replication. |
| Indications | – Used in combination with other antiviral medications to treat chronic hepatitis C virus (HCV) infections of genotypes 1-6.<br>- Also indicated for HCV and HIV co-infected patients. |
| Dosage Forms | Tablets (200 mg, 400 mg), oral pellets (150 mg, 200 mg per packet) |
| Administration | Taken orally once daily, with or without food. The typical dose is 400 mg once daily. |
| Pharmacokinetics | – Absorbed rapidly with peak plasma concentration reached in 0.5-2 hours.<br>- Eliminated primarily through urine (80%), with minor elimination via feces (14%) and respiration (2.5%).<br>- Half-life: Approximately 27 hours for the active metabolite GS-331007. |
| Side Effects | – Common: Fatigue, headache, nausea, trouble sleeping, anemia.<br>- Serious: Severe allergic reactions, reactivation of hepatitis B virus. |
| Precautions | – Monitor for signs of hepatitis B reactivation.<br>- Not recommended as monotherapy; always use in combination with other antiviral agents. |
| Storage | Store below 86°F (30°C) in the original packaging. |
| Developer | Gilead Sciences |
| Approval Date | FDA approval in December 2013 |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
